iShares Biotechnology ETF
832 hedge funds and large institutions have $4.71B invested in iShares Biotechnology ETF in 2023 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 165 increasing their positions, 338 reducing their positions, and 62 closing their positions.
1.47% more ownership
Funds ownership: 65.56% → 67.03% (+1.5%)
2% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 62
1% less funds holding
Funds holding: 843 → 832 (-11)
8% less capital invested
Capital invested by funds: $5.12B → $4.71B (-$406M)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
51% less repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 338
74% less call options, than puts
Call options by funds: $208M | Put options by funds: $806M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$167M |
| 2 |
IUHSA
Itau Unibanco Holding S.A.
Sao Paulo,
Brazil
|
+$50.2M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$38.8M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12.5M |
| 5 |
Capital Fund Management (CFM)
Paris,
France
|
+$7.77M |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$189M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$31.3M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$26.7M |
| 4 |
E
Ergoteles
New York
|
-$25.7M |
| 5 |
JP Morgan Chase
New York
|
-$24.8M |
IBB Hedge Fund Activity: Q3 2023 in Review
832 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2023, worth a combined $4.71B — down 7.9% from $5.12B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of IBB and 61 opened new positions — a net loss of 1 holder — while 338 trimmed existing stakes and 165 added.
The largest buyer was Goldman Sachs, adding an estimated $167M. The largest seller was Bank of America, cutting an estimated $189M.
- 832 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2023, down from 843 in Q2 2023.
- Funds reported $4.71B of iShares Biotechnology ETF stock for Q3 2023, down 7.9% quarter-over-quarter.
- 61 funds opened new iShares Biotechnology ETF positions in Q3 2023 and 62 closed out, a net change of -1 holder.
- The largest iShares Biotechnology ETF buyer in Q3 2023 was Goldman Sachs, an estimated $167M added.
- The largest iShares Biotechnology ETF seller in Q3 2023 was Bank of America, an estimated $189M sold.
Based on aggregated 13F filings for Q3 2023.